Combinatorial targeting of receptor tyrosine kinases (such as the IGF-1R) and their downstream signaling mediators is a very promising approach to develop more efficient anti-cancer therapies [16], [17], [22], [42]–[44]. The gene discussed is IGF1R; the disease is cancer.